Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 5/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784413 | 0.88 | BTN3A1 (0.52) | BTN3A1ELANEHTT | |
| SCHEMBL15052723 | 0.88 | BTN3A1 (0.52) | BTN3A1ELANEHTT | |
| SCHEMBL17198445 | 0.88 | BTN3A1 (0.52) | BTN3A1ELANEHTT | |
| SCHEMBL31355405 | 0.85 | BTN3A1 (0.45) | BTN3A1ELANEPRTN3MEN1KMT2A | |
| SCHEMBL26567942 | 0.81 | BTN3A1 (0.46) | BTN3A1ELANEPRTN3MEN1KMT2A | |
| SCHEMBL790348 | 0.79 | BTN3A1 (0.50) | BTN3A1ELANEL3MBTL1KMT2A | |
| SCHEMBL23391280 | 0.79 | MEN1 (0.40) | BTN3A1ELANEMEN1KMT2AALDH1A1 | |
| SCHEMBL15055604 | 0.79 | MEN1 (0.40) | BTN3A1ELANEMEN1KMT2AALDH1A1 | |
| SCHEMBL784174 | 0.76 | BTN3A1 (0.43) | BTN3A1ELANEPRTN3ATML3MBTL1 | |
| SCHEMBL16566342 | 0.76 | BTN3A1 (0.54) | BTN3A1ELANEL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | BTN3A1 3215/4885ELANE 1558/4885PRTN3 595/4885 |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | BTN3A1 3215/4885ELANE 1558/4885PRTN3 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.